Get started
Author

Steve Devine

ORCID: 0000-0001-7731-759X
Observed ORCID: 0000-0001-7731-759X
OpenAlex ID: A5114071623
Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
2024 · Mark J. Levis, Mehdi Hamadani, et al. · Journal of Clinical Oncology · 225
Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al. · Clinical Cancer Research · 30
PDF
Stem Cell Transplantation Eliminates Alloantibody in a Highly Sensitized Patient1
2001 · Amelia Bartholomew, Dorie Sher, et al. · Transplantation · 15
Correction: Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2024 · David J. Chung, Nina Shah, et al. · Clinical Cancer Research · 2
PDF
Study Representativeness Table1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Study Representativeness Table1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Data from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Study Representativeness Table 1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Study Representativeness Table 1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Figure S1 from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Data from Randomized Phase II Trial of Dendritic Cell/Myeloma Fusion Vaccine with Lenalidomide Maintenance after Upfront Autologous Hematopoietic Cell Transplantation for Multiple Myeloma: BMT CTN 1401
2023 · David J. Chung, Nina Shah, et al.
Works count: 14
Citation count: 272
H-index: 3
I10-index: 3
Year
Topic
Type